Skip NavigationSkip to Content
Return Return to Search Results

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

  1. Author:
    Ricketts, Christopher J
    De Cubas, Aguirre A
    Fan, Huihui
    Smith, Christof C
    Lang, Martin
    Reznik, Ed
    Bowlby, Reanne
    Gibb, Ewan A
    Akbani, Rehan
    Beroukhim, Rameen
    Bottaro, Donald P
    Choueiri, Toni K
    Gibbs, Richard A
    Godwin, Andrew K
    Haake, Scott
    Hakimi, A Ari
    Henske, Elizabeth P
    Hsieh, James J
    Ho, Thai H
    Kanchi, Rupa S
    Krishnan, Bhavani
    Kwaitkowski, David J
    Lui, Wembin
    Merino, Maria J
    Mills, Gordon B
    Myers, Jerome
    Nickerson, Michael L
    Reuter, Victor E
    Schmidt, Laura S
    Shelley, C Simon
    Shen, Hui
    Shuch, Brian
    Signoretti, Sabina
    Srinivasan, Ramaprasad
    Tamboli, Pheroze
    Thomas, George
    Vincent, Benjamin G
    Vocke, Cathy D
    Wheeler, David A
    Yang, Lixing
    Kim, William T
    Robertson, A Gordon
    Spellman, Paul T
    Rathmell, W Kimryn
    Linehan, W Marston

  2. Author Address

    Urologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA., Vanderbilt University School of Medicine, Nashville, TN 37232, USA., Van Andel Research Institute, Grand Rapids, MI 49503, USA., Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Canada 39;s Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada., The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., The Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA., Dana-Farber Cancer Institute, Boston, MA 02215, USA., Baylor College of Medicine, Houston, TX 77030, USA., University of Kansas Medical Center, Kansas City, KS 66206, USA., Brigham and Women 39;s Hospital, Boston, MA 02115, USA., Washington University School of Medicine, St. Louis, MO 63110, USA., Mayo Clinic Arizona, Phoenix, AZ 85054, USA., Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA., Centura Health, Centennial, CO 80112, USA., Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA., Urologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA; Basic Science Program, Leidos Biomedical Research, Inc. Frederick National Laboratory of Cancer Research, Frederick, MD 21702, USA., Leukemia Therapeutics LLC., Hull, MA 02045, USA., Yale University, New Haven, CT 06520, USA., Oregon Health & Science University, Portland, OR 97239, USA., Harvard Medical School, Boston, MA 02115, USA., Urologic Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD 20892, USA. Electronic address: wml@nih.gov.,
    1. Year: 2018
    2. Date: Apr 03
  2. Journal: Cell Reports
    1. 23
    2. 1
    3. Pages: 313-326.e5
  4. Type of Article: Article
  1. Abstract:

    Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.celrep.2018.03.075
  3. PMID: 29617669
  4. View record in Web of Science®
  5. WOS: 000429092900026
  6. PII : S2211-1247(18)30436-4

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel